Generation of rapid, strong and long-lasting antibody responses is crucial for development of effective vaccines against infectious diseases.
Vaccibody has over the last years generated promising pre-clinical data in different infectious disease models like SARS-CoV-2, Influenza, Ebola, Herpes Simplex Virus 2 and Tuberculosis.
The studies have shown that Vaccibody vaccines are able to protect against infectious diseases through generation of neutralizing antibodies and CD4+ T cell responses after a single administration with a needle-free jet injector.
Research is being conducted to leverage Vaccibody’s vaccine technology to develop vaccines to prevent or treat infectious diseases. Vaccibody will initiate a phase 1/2 trial to evaluate two next-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern during second half of 2021. The 2-armed strategy aims to develop two candidates for the broad population. First, a second-generation vaccine candidate encoding the receptor binding domain (RBD) derived from the South African beta variant of concern. And second, a third-generation T cell based vaccine candidate, encoding multiple validated immunodominant, conserved T cell epitopes spanning multiple antigens across the SARS-CoV-2 genome. Vaccibody has entered into an exclusive collaboration and license agreement with Adaptive Biotechnologies to use their validated shared SARS-CoV- 2 T cell epitopes in the T cell vaccine candidate.